BioXcel Therapeutics (BTAI) Stock Forecast, Price Target & Predictions
BTAI Stock Forecast
BioXcel Therapeutics stock forecast is as follows: an average price target of $1.00 (represents a 181.53% upside from BTAI’s last price of $0.36) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
BTAI Price Target
The average price target for BioXcel Therapeutics (BTAI) is $1.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $1.00 to $1.00. This represents a potential 181.53% upside from BTAI's last price of $0.36.
BTAI Analyst Ratings
According to 8 Wall Street analysts, BioXcel Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for BTAI stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
BioXcel Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Graig Suvannavejh | Mizuho Securities | $1.00 | $0.59 | 69.81% | 181.53% |
| Apr 15, 2024 | Raghuram Selvaraju | H.C. Wainwright | $10.00 | $2.90 | 244.83% | 2715.32% |
| Aug 15, 2023 | Graig Suvannavejh | Mizuho Securities | $4.00 | $3.98 | 0.63% | 1026.13% |
| Jan 03, 2023 | H.C. Wainwright | $73.00 | $21.48 | 239.85% | 20451.80% | |
| Nov 11, 2022 | Guggenheim | $25.00 | $14.82 | 68.69% | 6938.29% |
The latest BioXcel Therapeutics stock forecast, released on Sep 23, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $1.00, which represents a 69.81% increase from the stock price at the time of the forecast ($0.59), and a 181.53% increase from BTAI last price ($0.36).
BioXcel Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $1.00 | $5.50 |
| Last Closing Price | $0.36 | $0.36 | $0.36 |
| Upside/Downside | -100.00% | 181.53% | 1448.42% |
In the current month, the average price target of BioXcel Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to BioXcel Therapeutics's last price of $0.36. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 21, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 15, 2023 | Wells Fargo | Buy | Buy | Hold |
| May 26, 2023 | Goldman Sachs | Neutral | Neutral | Hold |
| Mar 21, 2023 | Piper Sandler | Buy | Buy | Hold |
| Mar 10, 2023 | Oppenheimer | Outperform | Initialise | |
| Mar 10, 2023 | JonesTrading | Buy | Initialise | |
| Mar 10, 2023 | Maxim Group | Buy | Initialise | |
| Dec 01, 2022 | Goldman Sachs | Neutral | Upgrade | |
| Nov 11, 2022 | Guggenheim | Buy | Buy | Hold |
BioXcel Therapeutics's last stock rating was published by H.C. Wainwright on Oct 21, 2024. The company gave BTAI a "Buy" rating, the same as its previous rate.
BioXcel Therapeutics Financial Forecast
BioXcel Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $376.00K | - | - | $206.00K | $238.00K | $137.00K | - | - |
| Avg Forecast | $1.70M | $1.50M | $1.40M | $1.30M | $689.23K | $1.33M | $762.50K | $450.00K | $742.86K | $626.00K | $453.89K | $389.00K | $1.08M | $1.00M | $125.00K | $9.90K |
| High Forecast | $2.44M | $2.15M | $2.01M | $1.86M | $987.68K | $1.37M | $762.75K | $644.86K | $1.27M | $628.00K | $650.43K | $557.45K | $1.55M | $1.00M | $125.00K | $11.88K |
| Low Forecast | $1.14M | $1.00M | $936.23K | $869.35K | $460.91K | $1.29M | $762.25K | $300.93K | $317.46K | $624.00K | $303.53K | $260.14K | $722.11K | $1.00M | $125.00K | $7.92K |
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 8 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | 0.51% | - | - | 0.53% | 0.22% | 0.14% | - | - |
BioXcel Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $450.00K, with a low forecast of $300.93K, and a high forecast of $644.86K. BTAI's average Quarter revenue forecast represents a 19.68% increase compared to the company's last Quarter revenue of $376.00K (Dec 23).
BioXcel Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 8 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | $-19.88M | - | - | $-49.43M | $-51.89M | $-38.99M | $-31.39M | $-26.30M |
| Avg Forecast | $340.00K | $300.00K | $280.00K | $260.00K | $137.84K | $265.52K | $152.50K | $90.00K | $148.57K | $125.20K | $90.78K | $77.80K | $215.96K | $200.96K | $-32.21M | $-22.39M |
| High Forecast | $487.23K | $429.91K | $401.25K | $372.59K | $197.53K | $273.38K | $152.55K | $128.97K | $253.97K | $125.60K | $130.09K | $111.49K | $309.48K | $200.96K | $-25.77M | $-17.91M |
| Low Forecast | $227.37K | $200.62K | $187.25K | $173.87K | $92.18K | $257.66K | $152.45K | $60.19K | $63.49K | $124.80K | $60.70K | $52.03K | $144.42K | $200.96K | $-38.65M | $-26.86M |
| Surprise % | - | - | - | - | - | - | - | - | -133.77% | - | - | -635.34% | -240.26% | -194.02% | 0.97% | 1.18% |
undefined analysts predict BTAI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than BioXcel Therapeutics's previous annual EBITDA (undefined) of $NaN.
BioXcel Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 8 | 10 |
| Net Income | - | - | - | - | - | - | - | - | $-22.26M | - | - | $-51.03M | $-58.09M | $-44.62M | $-31.46M | $-26.38M |
| Avg Forecast | $-11.87M | $-16.53M | $-19.08M | $-19.08M | $-19.39M | $-21.43M | $-30.21M | $-28.61M | $-38.86M | $-54.00M | $-73.90M | $-68.61M | $-60.29M | $-52.77M | $-32.29M | $-22.45M |
| High Forecast | $-6.76M | $-9.41M | $-10.86M | $-10.86M | $-15.03M | $-12.20M | $-17.20M | $-16.29M | $-26.57M | $-30.75M | $-42.08M | $-39.07M | $-34.32M | $-52.77M | $-25.83M | $-17.96M |
| Low Forecast | $-18.55M | $-25.84M | $-29.81M | $-29.81M | $-23.75M | $-33.49M | $-47.21M | $-44.72M | $-48.77M | $-84.40M | $-115.50M | $-107.24M | $-94.22M | $-52.77M | $-38.75M | $-26.94M |
| Surprise % | - | - | - | - | - | - | - | - | 0.57% | - | - | 0.74% | 0.96% | 0.85% | 0.97% | 1.18% |
BioXcel Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BTAI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
BioXcel Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 8 | 10 |
| SG&A | - | - | - | - | - | - | - | - | $9.60M | - | - | $23.59M | $20.66M | $17.05M | $12.92M | $11.64M |
| Avg Forecast | $83.91M | $74.04M | $69.11M | $64.17M | $34.02M | $65.53M | $37.64M | $22.21M | $36.67M | $30.90M | $22.40M | $19.20M | $53.30M | $49.57M | $6.17M | $488.57K |
| High Forecast | $120.25M | $106.10M | $99.03M | $91.96M | $48.75M | $67.47M | $37.65M | $31.83M | $62.68M | $31.00M | $32.11M | $27.52M | $76.38M | $49.57M | $6.17M | $586.25K |
| Low Forecast | $56.12M | $49.51M | $46.21M | $42.91M | $22.75M | $63.59M | $37.63M | $14.85M | $15.67M | $30.80M | $14.98M | $12.84M | $35.64M | $49.57M | $6.17M | $390.85K |
| Surprise % | - | - | - | - | - | - | - | - | 0.26% | - | - | 1.23% | 0.39% | 0.34% | 2.10% | 23.82% |
BioXcel Therapeutics's average Quarter SG&A projection for Mar 24 is $22.21M, based on 4 Wall Street analysts, with a range of $14.85M to $31.83M. The forecast indicates a 131.31% rise compared to BTAI last annual SG&A of $9.60M (Dec 23).
BioXcel Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 8 | 10 |
| EPS | - | - | - | - | - | - | - | - | $-0.76 | - | - | $-1.78 | $-2.07 | $-1.59 | $-1.12 | $-1.08 |
| Avg Forecast | $-0.28 | $-0.39 | $-0.45 | $-0.45 | $-0.46 | $-0.51 | $-0.71 | $-0.67 | $-0.92 | $-1.27 | $-1.74 | $-1.62 | $-1.42 | $-1.31 | $-1.10 | $-0.95 |
| High Forecast | $-0.16 | $-0.22 | $-0.26 | $-0.26 | $-0.35 | $-0.29 | $-0.41 | $-0.38 | $-0.63 | $-0.73 | $-0.99 | $-0.92 | $-0.81 | $-1.31 | $-1.10 | $-0.95 |
| Low Forecast | $-0.44 | $-0.61 | $-0.70 | $-0.70 | $-0.56 | $-0.79 | $-1.11 | $-1.05 | $-1.15 | $-1.99 | $-2.72 | $-2.53 | $-2.22 | $-1.31 | $-1.10 | $-0.95 |
| Surprise % | - | - | - | - | - | - | - | - | 0.83% | - | - | 1.10% | 1.46% | 1.21% | 1.02% | 1.13% |
According to undefined Wall Street analysts, BioXcel Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BTAI previous annual EPS of $NaN (undefined).
BioXcel Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.52 | $70.00 | 13361.54% | Buy |
| ELEV | Elevation Oncology | $0.67 | $9.00 | 1243.28% | Buy |
| INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| BTAI | BioXcel Therapeutics | $0.39 | $1.00 | 156.41% | Buy |
| MREO | Mereo BioPharma Group | $3.40 | $8.00 | 135.29% | Buy |
| VKTX | Viking Therapeutics | $46.70 | $97.80 | 109.42% | Buy |
| APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.28 | $8.25 | 92.76% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| MDGL | Madrigal Pharmaceuticals | $306.08 | $315.75 | 3.16% | Buy |
| EXEL | Exelixis | $34.69 | $30.89 | -10.95% | Buy |
| TGTX | TG Therapeutics | $33.57 | $23.75 | -29.25% | Buy |